News

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...
Zepbound outperforms Wegovy in head-to-head weight loss trial
Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
EconoTimes2d
Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial
Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...
Yahoo Finance3d
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Nasdaq2d
Lilly's Zepbound Outperforms Wegovy In Phase 3b Trial For Weight Reduction
(RTTNews) - Eli Lilly and Co. (LLY) announced that Zepbound (tirzepatide) demonstrated a significantly greater weight reduction compared to Wegovy (semaglutide) in all comparisons conducted during ...